argx-117
mAbexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
8
Phase 3
3
Phase 4
0
Earliest trial started Aug 3, 2020 (NCT04532125)
Timeline
Indications
Mechanism of action
- Complement C2INHIBITOR
C2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314673 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07284420 | Phase 2 | Dec 31, 2025 | argenx |
| NCT07091630 | Phase 3 | Sep 16, 2025 | argenx |
| NCT06920004 | Phase 3 | Aug 22, 2025 | argenx |
| NCT06742190 | Phase 3 | Dec 31, 2024 | argenx |
| NCT06284954 | Phase 2 | Aug 20, 2024 | argenx |
| NCT05907096 | Phase 2 | Oct 31, 2023 | argenx |
| NCT05405361 | Phase 2 | Oct 1, 2022 | argenx |
| NCT05225675 | Phase 2 | Mar 31, 2022 | argenx |
| NCT04532125 | Phase 1 | Aug 3, 2020 | argenx |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| argenx | For profit | 9 | 9 | 3 | 2020 |
1 organizations
Page 1 / 1